Efficacy of Gemcitabine-based chemotherapy in clear cell sarcoma of soft tissue.
Cojocaru, Elena Thway, Khin Fisher, Cyril Messiou, Christina Zaidi, Shane Miah, Aisha B Benson, Charlotte Gennatas, Spyridon Huang, Paul Jones, Robin L
Cojocaru, Elena
Thway, Khin
Fisher, Cyril
Messiou, Christina
Zaidi, Shane
Miah, Aisha B
Benson, Charlotte
Gennatas, Spyridon
Huang, Paul
Jones, Robin L
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2020-12
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background/aim: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma.
Patients and methods: We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital.
Results: Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months.
Conclusion: Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.
Citation
Cojocaru E, Thway K, Fisher C, Messiou C, Zaidi S, Miah AB, Benson C, Gennatas S, Huang P, Jones RL. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Res. 2020 Dec;40(12):7003-7007. doi: 10.21873/anticanres.14725
Type
Article
Other
Other